BioWorld

Oct. 14, 2003

FDA Accepts ImClone's Erbitux Filing, Grants It Priority Review

Elixir Pharmaceuticals Gets $19M In Second B' Round

Georgia, Among Others, Seeking To Grow Through Life Sciences

Xcyte Seeking $75M In Second Attempt At Initial Public Offering

Other News To Note

Corgentech, BMS Enter Graft Deal Valued At Up To $250M

With two Phase III trials under way testing its treatment to prevent vein-graft failure after surgery, Corgentech Inc. is joining with Bristol-Myers Squibb Co. in a deal that's expected to get revenue flowing better. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...